| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7c7159366be37ecf8a4c595cfa235a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e388911162aa60ca4fbf1d0dc2a6bca1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12 |
| filingDate |
1999-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b8769d69164a4171831fb70ed0ae806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d38ffabf27a928925839bba06bf73358 |
| publicationDate |
2001-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1103561-A1 |
| titleOfInvention |
Hla-a2 restraint tumor antigen peptide originating in sart-1 |
| abstract |
An HLA-A2 restricted tumor antigen peptide originated from SART-1,nderivatives thereof having characteristics functionally equivalent thereto;ntherapeutic, prophylactic or diagnostic agents for tumors which utilize thentumor antigen peptide or its derivative, a recombinant DNA, recombinantnpolypeptide or antibody related to said tumor antigen peptide, or usenthereof; an antigen presenting cell presenting the said tumor antigennpeptide or use thereof; cytotoxic T lymphocyte specific for said tumornantigen peptide or use thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005029083-A1 |
| priorityDate |
1998-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |